Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Peiper

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Biological Chemistry|March 30, 2002
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonistsWen-Bo Zhang, Jean-Marc Navenot, Bodduluri Haribabu, et al.
Plos One|October 3, 2012
Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft modelSimone Buraschi, Thomas Neill, Rick T Owens, et al.
Biochemical and Biophysical Research Communications|March 12, 2004
Metastin and its variant forms suppress migration of pancreatic cancer cellsToshihiko Masui, Ryuichiro Doi, Tomohiko Mori, et al.
Bioorganic & Medicinal Chemistry Letters|June 10, 2008
Identification of novel non-peptide CXCR4 antagonists by ligand-based design approachSatoshi Ueda, Manabu Kato, Shinsuke Inuki, et al.
International Journal of Cancer|December 30, 2009
Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4Koji Nishizawa, Hiroyuki Nishiyama, Shinya Oishi, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 28, 2022
Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathwayXiang Li, Shaomin Wang, Wei Mu, et al.
Chembiochem : a European Journal of Chemical Biology|April 17, 2008
Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4Shinya Oishi, Ryo Masuda, Barry Evans, et al.
Plos One|October 21, 2016
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell CarcinomaWei Jiang, Essel Dulaimi, Karthik Devarajan, et al.
Organic & Biomolecular Chemistry|December 6, 2005
Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffoldsHirokazu Tamamura, Ai Esaka, Teppei Ogawa, et al.
Advances in Experimental Medicine and Biology|April 30, 2009
Development of chemokine receptor CXCR4 antagonists using bio-mimetic strategyHirokazu Tamamura, Tomohiro Tanaka, Hiroshi Tsutsumi, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Biological Chemistry|March 30, 2002
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonistsWen-Bo Zhang, Jean-Marc Navenot, Bodduluri Haribabu, et al.
Plos One|October 3, 2012
Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft modelSimone Buraschi, Thomas Neill, Rick T Owens, et al.
Biochemical and Biophysical Research Communications|March 12, 2004
Metastin and its variant forms suppress migration of pancreatic cancer cellsToshihiko Masui, Ryuichiro Doi, Tomohiko Mori, et al.
Bioorganic & Medicinal Chemistry Letters|June 10, 2008
Identification of novel non-peptide CXCR4 antagonists by ligand-based design approachSatoshi Ueda, Manabu Kato, Shinsuke Inuki, et al.
International Journal of Cancer|December 30, 2009
Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4Koji Nishizawa, Hiroyuki Nishiyama, Shinya Oishi, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 28, 2022
Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathwayXiang Li, Shaomin Wang, Wei Mu, et al.
Chembiochem : a European Journal of Chemical Biology|April 17, 2008
Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4Shinya Oishi, Ryo Masuda, Barry Evans, et al.
Plos One|October 21, 2016
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell CarcinomaWei Jiang, Essel Dulaimi, Karthik Devarajan, et al.
Organic & Biomolecular Chemistry|December 6, 2005
Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffoldsHirokazu Tamamura, Ai Esaka, Teppei Ogawa, et al.
Advances in Experimental Medicine and Biology|April 30, 2009
Development of chemokine receptor CXCR4 antagonists using bio-mimetic strategyHirokazu Tamamura, Tomohiro Tanaka, Hiroshi Tsutsumi, et al.
Pageof 9